deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT03375164

A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

Systemic Gene Delivery Phase I/IIa Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MHCK7.Micro-dystrophin (microDys-IV-001)

Sponsor: Sarepta Therapeutics, Inc.

Conditions Duchenne Muscular Dystrophy
Interventions delandistrogene moxeparvovec
Updated 19 times since 2017 Last updated: Nov 12, 2024 Started: Jan 4, 2018 Primary completion: Apr 25, 2023 Completion: Apr 25, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03375164, this PHASE1/PHASE2 trial focuses on Duchenne Muscular Dystrophy and remains completed. Sponsored by Sarepta Therapeutics, Inc., it has been updated 19 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Jan 2019 · 4 months · monthly snapshot~Jan 2019 – ~Jul 2019 · 6 months · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Dec 2019 · 4 months · monthly snapshot~Dec 2019 – ~Apr 2020 · 4 months · monthly snapshot~Apr 2020 – ~Dec 2020 · 8 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Mar 2022 · 14 months · monthly snapshot~Mar 2022 – ~Sep 2022 · 6 months · monthly snapshot~Sep 2022 – ~Jun 2023 · 9 months · monthly snapshot~Jun 2023 – ~Aug 2023 · 2 months · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Jun 2024 · 9 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – present · 19 months · monthly snapshot

Change History

19 versions recorded

  1. Dec 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Dec 2024 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jun 2024 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  5. Sep 2023 — Jun 2024 [monthly]

    Completed PHASE1_PHASE2

▶ Show 14 earlier versions

  1. Aug 2023 — Sep 2023 [monthly]

    Completed PHASE1_PHASE2

  2. Jun 2023 — Aug 2023 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  3. Sep 2022 — Jun 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Mar 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Jan 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Apr 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  8. Dec 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  9. Aug 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  10. Jul 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  11. Jan 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  12. Sep 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  13. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE1_PHASE2

  14. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sarepta Therapeutics, Inc.
Data source: Sarepta Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations